This policy statement is approved by Halton, Knowsley, Liverpool, Southport and Formby, South Sefton, St Helens, Warrington and West Lancashire

Halton | Knowsley | Liverpool | Southport and Formby | South Sefton | St Helens | Warrington | West Lancashire

PAN MERSEY AREA PRESCRIBING COMMITTEE
PRESCRIBING POLICY STATEMENT
REF: PS135 FINAL
FIRST APC BOARD DATE: 08 MAY 2013
LAST APC BOARD DATE: 28 MAR 2018

NHS Pan Mersey
Area Prescribing Committee

TOCILIZUMAB (RoActemra®) in rheumatological conditions

RED

The Pan Mersey Area Prescribing Committee recommends the prescribing of tocilizumab infusion and subcutaneous injection (RoActemra®) for the treatment of rheumatoid arthritis and adult-onset Still's disease, and the infusion for juvenile idiopathic arthritis, as described below.

Rheumatoid arthritis (RA): The Pan Mersey Area Prescribing Committee (APC) recommends prescribing tocilizumab injection for rheumatoid arthritis in accordance with NICE TA375 (January 2016), and in accordance with the Pan Mersey Rheumatoid Arthritis Biologics Pathway. NICE TA375 recommends tocilizumab with methotrexate or as monotherapy, as a treatment option for adults with severe active rheumatoid arthritis (DAS28>5.1) who have had an inadequate response to intensive therapy with a combination of disease-modifying anti-rheumatic drugs (DMARDs). The Pan Mersey RA biologics pathway recommends use with non-methotrexate DMARDs as an option in patients who cannot have methotrexate. The Pan Mersey APC recommends tocilizumab as a treatment option for severe rheumatoid arthritis where the disease has responded inadequately to DMARDs and a TNF inhibitor and the person cannot receive rituximab because of a contraindication to rituximab, or because rituximab is withdrawn because of an adverse event OR the disease has responded inadequately to one or more TNF inhibitor treatments and to rituximab, in accordance with NICE TA247 (February 2012).

Adult-onset Still's disease (AOSD): The Pan Mersey APC recommends tocilizumab as an option for treating AOSD within the criteria commissioned by Pan Mersey CCGs.

Juvenile idiopathic arthritis (JIA): The Pan Mersey APC recommends tocilizumab as an option for treating systemic and polyarticular JIA, in accordance with NICE TA238 (December 2011) and NICE TA373 (December 2015. Further details are contained in the Pan Mersey statement on Biologic agents in management of Juvenile Idiopathic Arthritis. The subcutaneous injection is not licensed for JIA.

The manufacturer must provide tocilizumab with the discount agreed as part of the patient access scheme.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.